Claims for Patent: 6,399,612

Summary for Patent: 6,399,612

Title:	Heteroaryl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
Abstract:	Heteroaryl butyric acid compounds and derivatives are described as well as methods for the preparation and pharmaceutical compositions of same, which are useful as inhibitors of matrix metalloproteinases, particularly gelatinase A, collagenase-3, and stromelysin-1 and for the treatment of multiple sclerosis, atherosclerotic plaque rupture, aortic aneurism, heart failure, restenosis, periodontal disease, corneal ulceration, treatment of burns, decubital ulcers, wound healing, cancer, inflammation, pain, arthritis, osteoporosis, or other autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes or other activated migrating cells, acute and chronic neurodegenerative disorders including stroke, head trauma, spinal cord injury, Alzheimer\'s disease, amyotrophic lateral sclerosis, cerebral amyloid angiopathy, AIDS, Parkinson\'s disease, Huntington\'s disease, prion diseases, myasthenia gravis, and Duchenne\'s muscular dystrophy.
Inventor(s):	Purchase, Jr.; Claude Forsey (Ann Arbor, MI), Roth; Bruce David (Plymouth, MI), Schielke; Gerald Paul (Ann Arbor, MI), Walker; Lary Craswell (Ann Arbor, MI), White; Andrew David (Pinckney, MI)
Assignee:	Warner-Lambert Company (Morris Plains, NJ)
Application Number:	09/647,400
Patent Claims:	1. A compound of the formula ##STR69## wherein m is an integer from 0 to 4; A is ##STR70## R and R.sup.1 are the same or different and are hydrogen, alkyl, halogen, nitro, cyano, trifluoromethyl, OCF.sub.3, OCF.sub.2 H, OCH.sub.2 F, --OR.sup.6 wherein R.sup.6 is hydrogen, alkyl, aryl, arylalkyl, heteroaryl, or cycloalkyl, ##STR71## wherein R.sup.6 and R.sup.6a are the same or different and are as defined above for R.sup.6, ##STR72## wherein R.sup.6 is as defined above, ##STR73## wherein R.sup.6 is as defined above, ##STR74## wherein R.sup.6 is as defined above, --SR.sup.6 wherein R.sup.6 is a defined above, ##STR75## wherein R.sup.6 is as defined above, --CH.sub.2 --OR.sup.6 wherein R.sup.6 is as defined above, ##STR76## wherein R.sup.6 and R.sup.6a are the same or different and are R.sup.6a as defined above for R.sup.6 ##STR77## wherein R.sup.6 and R.sup.6a are the same or different and are as defined above for R.sup.6, ##STR78## wherein R.sup.6 is as defined above for, ##STR79## wherein R.sup.6 is as defined above, cycloalkyl, or heteroaryl; R.sup.3, R.sup.3a, R.sup.4, and R.sup.4a are the same or different and are hydrogen, or fluorine; and corresponding isomers thereof; or a pharmaceutically acceptable salt thereof. 2. A compound of the formula ##STR80## wherein m is an integer from 0 to 4; A is ##STR81## R and R.sup.1 are the same or different and are hydrogen, alkyl, halogen, nitro, cyano, trifluoromethyl, OCF.sub.3, OCF.sub.2 H, OCH.sub.2 F, --OR.sup.6 wherein R.sup.6 is hydrogen, alkyl, aryl, arylalkyl, heteroaryl, or cycloalkyl, ##STR82## wherein R.sup.6 and R.sup.6a are the same or different and are as defined above for R.sup.6, ##STR83## wherein R.sup.6 is as defined above, ##STR84## wherein R.sup.6 is as defined above, ##STR85## wherein R.sup.6 is as defined above, --SR.sup.6 wherein R.sup.6 is as defined above, ##STR86## wherein R.sup.6 is as defined above, --CH.sub.2 --OR.sup.6 wherein R.sup.6 is as defined above, ##STR87## wherein R.sup.6 and R.sup.6a are the same or different and are as defined above for R.sup.6 ##STR88## wherein R.sup.6 and R.sup.6a are the same or different and are as defined above for R.sup.6, ##STR89## wherein R.sup.6 is as defined above, ##STR90## wherein R.sup.6 is as defined above, cycloalkyl, or heteroaryl; R.sup.3, R.sup.3a, R.sup.4, and R.sup.4a are the same or different and are hydrogen, fluorine, alkyl, --(CH.sub.2).sub.n -aryl wherein n is an integer from 1 to 6, --(CH.sub.2).sub.n -heteroaryl wherein n is as defined above, --(CH.sub.2).sub.n -cycloalkyl wherein n is as defined above, --(CH.sub.2).sub.p --X--(CH.sub.2).sub.q -aryl wherein X is O, S, SO, SO.sub.2, or NH, and p and q are each zero or an integer of 1 to 6, and the sum of p+q is not greater than six, --(CH.sub.2).sub.p --X--(CH.sub.2).sub.q -heteroaryl wherein X, p, and q are as defined above, or --(CH.sub.2).sub.n --R.sup.7 wherein R.sup.7 is N-phthalimido, N-2,3-napthylimido, --OR.sup.6 wherein R.sup.6 is as defined above, ##STR91## wherein R.sup.6 and R.sup.6a are the same or different and are as defined above for R.sup.6, --SR.sup.6 wherein R.sup.6 is as defined above, ##STR92## wherein R.sup.6 is as defined above, ##STR93## wherein R.sup.6 is as defined above, ##STR94## wherein R.sup.6 is as defined above, ##STR95## wherein R.sup.6 and R.sup.6a are the same or different and are as defined above for R.sup.6, ##STR96## wherein R.sup.6 is as defined above, ##STR97## wherein R.sup.6 is as defined above, ##STR98## wherein R.sup.6 is as defined above, or ##STR99## wherein R.sup.6 and R.sup.6a are the same or different and are as defined above for R.sup.6, and n is as defined above; with the proviso that at least one of R.sup.3, R.sup.3a, R.sup.4, or R.sup.4a is fluorine; and corresponding isomers thereof; or a pharmaceutically acceptable salt thereof. 3. A compound which is 4-[4-(5-chloro-thiophen-2-yl)-phenyl]-4-oxo-butyric acid. 4. A compound selected from the group consisting of: 4-[4-(5-Chloro-thiophen-2-yl)-phenyl]-4-hydroxyimino-butyric acid; 4-[4-(5-Chloro-thiophen-2-yl)-phenyl]-4-hydroxyimino-butyric acid, 2,2-dimethyl-propionyloxymethyl ester; 4-[4-(5-Chloro-thiophen-2-yl)-phenyl]-4-methoxyimino-butyric acid; 4-[4-(5-Bromo-thiophen-2-yl)-phenyl]-4-hydroxyimino-butyric acid; 4-[4-(5-Fluoro-thiophen-2-yl)-phenyl]-4-hydroxyimino-butyric acid; 4-[4-(5-Chloro-3-fluoro-thiophen-2-yl)-phenyl]-4-hydroxyimino-butyric acid; 4-Hydroxyimino-4-[4-(5-trifluoromethyl-thiophen-2-yl)-phenyl]-butyric acid; 4-[5-(4-Chloro-phenyl)-thiophen-2-yl]-4-hydroxyimino-butyric acid; 4-[5-(4-Bromo-phenyl)-thiophen-2-yl]-4-hydroxyimino-butyric acid; 4-[5-(4-Fluoro-phenyl)-thiophen-2-yl]-4-hydroxyimino-butyric acid; 4-[5-(4-Chloro-2-fluoro-phenyl)-thiophen-2-yl]-4-hydroxyimino-butyric acid; 4-[5-(4-Cyano-phenyl)thiophen-2-yl]-4-hydroxyimino-butyric acid; 4-Hydroxyimino-4-[5-(4-trifluoromethyl-phenyl)-thiophen-2-yl)-butyric acid; 4-Hydroxyimino-4-[5-(4-methylsulfanyl-phenyl)-thiophen-2-yl)-butyric acid; 4-[4-(5-Chloro-thiazol-2-yl)-phenyl]-4-hydroxyimino-butyric acid; 4-[4-(2-Chloro-thiazol-5-yl)-phenyl]-4-hydroxyimino-butyric acid; 4-[4-(5-Chloro-1,3,4-thiadiazol-2-yl)-phenyl]-4-hydroxyimino-butyric acid; 4-[5-(4-Chloro-phenyl)-pyrimidin-2-yl]-4-hydroxyimino-butyric acid; 4-[2-(4-Chloro-phenyl)-pyrimidin-5-yl]-4-hydroxyimino-butyric acid; 4-[4-(2-Chloro-pyrimidin-5-yl)-phenyl]-4-hydroxyimino-butyric acid; 4-[4-(5-Chloro-pyrimidin-2-yl)-phenyl]-4-hydroxyimino-butyric acid; 4-[5-(4-Chloro-phenyl)-pyrazin-2-yl]-4-hydroxyimino-butyric acid; 4-[4-(5-Chloro-pyrazin-2-yl)-phenyl]-4-hydroxyimino-butyric acid; 4-[4-(5-Fluoro-isoxazol-3-yl)-phenyl]-4-hydroxyimino-butyric acid; 4-[4-(3-Fluoro-isoxazol-5-yl)-phenyl]-4-hydroxyimino-butyric acid; 4-[4-(5-Fluoro-isothiazol-3-yl)-phenyl]-4-hydroxyimino-butyric acid; 4-[4-(3-Fluoro-isothiazol-5-yl)-phenyl]-4-hydroxyimino-butyric acid; 4-Hydroxyimino-4-[4-(2-methoxy-pyrimidin-5-yl)-phenyl-butyric acid; and 4-Hydroxyimino-4-(4-pyrazol-1-phenyl)-butyric acid. 5. A compound which is 4-[4-(5-Chloro-thiophen-2-yl)-phenyl-4-hydroxyimino-butyric acid. 6. A compound according to claim 2 wherein R.sup.3 and R.sup.3a are fluorine. 7. A compound according to claim 2 wherein R.sup.4 and R.sup.4a are fluorine. 8. A compound according to claim 2 wherein R.sup.3 is fluorine. 9. A compound according to claim 2 wherein R.sup.4 is fluorine. 10. A method of inhibiting a matrix metalloproteinase comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 11. A method of inhibiting gelatinase A comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 12. A method of inhibiting stromelysin-1 comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 13. A method of inhibiting collagenase-3 comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 14. A method of preventing atherosclerotic plaque rupture comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 15. A method of inhibiting aortic aneurism comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 16. A method of preventing restenosis comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 17. A method of controlling periodontal disease comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 18. A method of treating cornmeal ulceration comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 19. A method of treating bums comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 20. A method of treating decubital ulcers comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 21. A method of treatment for healing wounds comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 22. A method of treating arthritis comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 23. A method of treating osteoporosis comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 24. A method of treating autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 25. A method of treating multiple sclerosis comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 26. A method of treating inflammation and pain comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 27. A pharmaceutical composition comprising a compound according to claim 1 in admixture with a pharmaceutically acceptable excipient, diluent, or carrier. 28. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 in admixture with a pharmaceutically acceptable excipient, diluent, or carrier. 29. A method of inhibiting a matrix metalloproteinase comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 2 in unit dosage form. 30. A method of inhibiting gelatinase A comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 2 in unit dosage form. 31. A method of inhibiting stromelysin-1 comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 2 in unit dosage form. 32. A method of inhibiting collagenase-3 comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 2 in unit dosage form. 33. A method of preventing atherosclerotic plaque rupture comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 2 in unit dosage form. 34. A method of inhibiting aortic aneurism comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 2 in unit dosage form. 35. A method of preventing restenosis comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 2 in unit dosage form. 36. A method of controlling periodontal disease comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 2 in unit dosage form. 37. A method of treating cornmeal ulceration comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 2 in unit dosage form. 38. A method of treating bums comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 2 in unit dosage form. 39. A method of treating decubital ulcers comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 2 in unit dosage form. 40. A method of treatment for healing wounds comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 2 in unit dosage form. 41. A method of treating arthritis comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 2 in unit dosage form. 42. A method of treating osteoporosis comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 2 in unit dosage form. 43. A method of treating autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 2 in unit dosage form. 44. A method of treating multiple sclerosis comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 2 in unit dosage form. 45. A method of treating inflammation and pain comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 2 in unit dosage form. 46. A pharmaceutical composition comprising a compound according to claim 2 in admixture with a pharmaceutically acceptable excipient, diluent, or carrier. 47. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 2 in admixture with a pharmaceutically acceptable excipient, diluent, or carrier.

Details for Patent 6,399,612

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2017-10-06